Drugmaker AstraZeneca’s Market Value Soars Past £200 Billion
- Drugmaker became UK’s most valuable listed company in April
- Cancer medication has helped boost AstraZeneca’s revenue
This article is for subscribers only.
AstraZeneca Plc’s market value surged above £200 billion ($257 billion) for the first time after a big bet on cancer drugs helped drive a rally in the shares.
Shares climbed as much as 0.5% on Wednesday, extending an advance this year to 22%. The firm’s market value closed above £200 billion for the first time on Tuesday.